Compare Cassava Sciences Inc (FLNA) vs Newmont Corporation (NEM) Price & Performance

FLNA trades at $0.8136, down 0.26% today, with a bearish technical signal from moving averages but neutral oscillators. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though it has beaten EPS estimates in recent quarters. Recent positive news includes FDA lifting a clinical hold on its epilepsy drug, enabling Phase 2a studies.

The outlook remains high-risk due to persistent negative cash flows and lack of revenue, but analyst consensus is bullish with 67% buy ratings. Key risks include clinical trial execution and funding needs, while the FDA decision provides a potential catalyst for long-term investors focused on biotech turnaround stories.

Newmont Corporation (NEM) trades at $115.55, up 1.77% today, with a bearish technical signal despite strong fundamentals. The company reported record free cash flow of $5.3 billion in H1 2026 and has beaten earnings estimates for three consecutive quarters. Revenue grew to $22.67 billion in 2025, with net income margin expanding to 33.36%.

Outlook remains positive with a consensus price target of $136.83, implying 18% upside, supported by operational improvements and favorable gold prices. Risks include gold price volatility and execution of growth projects. Analyst sentiment is strongly bullish with 76% buy ratings and no sell recommendations.